A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function.
Standard
A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function. / Rudolph, Volker; Rudolph, Tanja Katharina; Kubala, Lukas; Clauberg, Navina; Maas, Renke; Pekarova, Michaela; Klinke, Anna; Lau, Denise; Szöcs, Katalin; Meinertz, Thomas; Böger, Rainer; Baldus, Stephan.
In: FREE RADICAL BIO MED, Vol. 47, No. 11, 11, 2009, p. 1584-1590.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left ventricular function.
AU - Rudolph, Volker
AU - Rudolph, Tanja Katharina
AU - Kubala, Lukas
AU - Clauberg, Navina
AU - Maas, Renke
AU - Pekarova, Michaela
AU - Klinke, Anna
AU - Lau, Denise
AU - Szöcs, Katalin
AU - Meinertz, Thomas
AU - Böger, Rainer
AU - Baldus, Stephan
PY - 2009
Y1 - 2009
N2 - Circulating levels of myeloperoxidase (MPO), a heme enzyme released upon activation of polymorphonuclear neutrophils, predict adverse outcome in patients with impaired left ventricular (LV) function. The MPO -463 G/A promoter polymorphism (rs 2333227) regulates MPO transcription, with the G allele being linked to increased protein expression. The aim of this study was to assess the prognostic information derived from the -463 G/A MPO polymorphism on outcomes of patients with impaired LV function. The -463 G/A promoter MPO genotype as well as MPO plasma levels were determined in 116 patients with impaired LV function. Patients were prospectively followed for a median of 1050 days. The GG genotype was associated with a decrease in overall survival (chi(2) 5.80; p=0.016). This association remained after multivariate adjustment for plasma levels of NT-proBNP, creatinine, hsCRP, and MPO; leukocyte count; and LV function (hazard ratio 3.16 (95% CI 1.17-8.53), p=0.024) and for classical cardiovascular risk factors (hazard ratio 2.88 (95% CI 1.13-7.33), p=0.026). Interestingly, we observed no association of the MPO polymorphism with total MPO protein concentration or MPO activity in plasma. The -463 G/A MPO polymorphism is linked to adverse clinical outcome of patients with impaired LV function. Further studies are needed to elucidate the value of this polymorphism for risk stratification.
AB - Circulating levels of myeloperoxidase (MPO), a heme enzyme released upon activation of polymorphonuclear neutrophils, predict adverse outcome in patients with impaired left ventricular (LV) function. The MPO -463 G/A promoter polymorphism (rs 2333227) regulates MPO transcription, with the G allele being linked to increased protein expression. The aim of this study was to assess the prognostic information derived from the -463 G/A MPO polymorphism on outcomes of patients with impaired LV function. The -463 G/A promoter MPO genotype as well as MPO plasma levels were determined in 116 patients with impaired LV function. Patients were prospectively followed for a median of 1050 days. The GG genotype was associated with a decrease in overall survival (chi(2) 5.80; p=0.016). This association remained after multivariate adjustment for plasma levels of NT-proBNP, creatinine, hsCRP, and MPO; leukocyte count; and LV function (hazard ratio 3.16 (95% CI 1.17-8.53), p=0.024) and for classical cardiovascular risk factors (hazard ratio 2.88 (95% CI 1.13-7.33), p=0.026). Interestingly, we observed no association of the MPO polymorphism with total MPO protein concentration or MPO activity in plasma. The -463 G/A MPO polymorphism is linked to adverse clinical outcome of patients with impaired LV function. Further studies are needed to elucidate the value of this polymorphism for risk stratification.
M3 - SCORING: Zeitschriftenaufsatz
VL - 47
SP - 1584
EP - 1590
JO - FREE RADICAL BIO MED
JF - FREE RADICAL BIO MED
SN - 0891-5849
IS - 11
M1 - 11
ER -